REGN.O
Latest Trade
620.21USDChange
0.00(0.00%)Volume
19Today's Range
-
--52 Week Range
-
664.64As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 620.21 |
|---|---|
Open | 0.00 |
Volume | 19 |
3M AVG Volume | 26.11 |
Today's High | -- |
Today's Low | -- |
52 Week High | 664.64 |
52 Week Low | 271.37 |
Shares Out (MIL) | 106.39 |
Market Cap (MIL) | 65,985.63 |
Forward P/E | 22.80 |
Dividend (Yield %) | -- |
Regeneron Announces Pricing Of Public Offering Of Senior Unsecured Notes
Adicet Bio Receives $10 Million Milestone Payment From Regeneron
Regeneron Pharmaceuticals Q2 GAAP Earnings Per Share $7.61
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.
Industry
Biotechnology & Drugs
Contact Info
777 Old Saw Mill River Rd
TARRYTOWN, NY
10591-6717
United States
+1.914.8477000
https://www.regeneron.com/Executive Leadership
P. Roy Vagelos
Chairman of the Board, Director
Leonard S. Schleifer
President, Chief Executive Officer, Director
George D. Yancopoulos
President, Chief Scientific Officer, Director
Robert E. Landry
Chief Financial Officer, Executive Vice President - Finance
Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Price To Earnings (TTM) | 24.01 |
|---|---|
Price To Sales (TTM) | 8.25 |
Price To Book (MRQ) | 7.26 |
Price To Cash Flow (TTM) | 20.58 |
Total Debt To Equity (MRQ) | 24.47 |
LT Debt To Equity (MRQ) | 7.90 |
Return on Investment (TTM) | 26.89 |
Return on Equity (TTM) | 21.62 |
Regeneron Pharmaceuticals Inc <REGN.O> beat second-quarter profit estimates on Wednesday, helped by higher sales of its eczema drug Dupixent and said it expects initial data from ongoing trials of its COVID-19 antibody cocktail next month.
Regeneron Pharmaceuticals Inc reported a quarterly profit on Wednesday that rose more than four times, helped by a $228 million gain and on higher sales of its blockbuster eczema treatment Dupixent.
Regeneron Pharmaceuticals Inc said on Monday that the COVID-19 antibody drug combination it is developing both prevented and treated the disease in rhesus macaques and hamsters, adding to hope that it might work for people.
U.S. Department of Health and Human Services (HHS):
The U.S. government signed a $450 million contract with Regeneron Pharmaceuticals Inc <REGN.O> for its potential COVID-19 antibody cocktail, the drugmaker said on Tuesday.
* REGENERON ANNOUNCES MANUFACTURING AND SUPPLY AGREEMENT FOR BARDA AND U.S. DEPARTMENT OF DEFENSE FOR REGN-COV2 ANTI-VIRAL ANTIBODY COCKTAIL
Regeneron Pharmaceuticals Inc said on Tuesday the U.S. government has granted the drugmaker a $450 million contract to make and supply its double antibody cocktail that is being tested against COVID-19.
Regeneron Pharmaceuticals Inc <REGN.O> said on Monday it has started late-stage clinical trials to assess the effectiveness of its antibody cocktail in preventing and treating COVID-19.
Regeneron Pharmaceuticals Inc said on Monday it began late-stage clinical trials to assess the effectiveness of its antibody cocktail in preventing and treating COVID-19.
* REGENERON ANNOUNCES START OF REGN-COV2 PHASE 3 COVID-19 PREVENTION TRIAL IN COLLABORATION WITH NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID)
Regeneron Pharmaceuticals Inc and Sanofi said on Thursday their rheumatoid arthritis drug Kevzara failed to meet the main goals of a U.S. study testing it in the most critically ill COVID-19 patients.
Regeneron Pharmaceuticals Inc and Sanofi said on Thursday their rheumatoid arthritis drug Kevzara failed to meet the main goals of a late-stage study testing it in COVID-19 patients.
* REGENERON AND SANOFI PROVIDE UPDATE ON KEVZARA® (SARILUMAB) PHASE 3 U.S. TRIAL IN COVID-19 PATIENTS
* REGENERON PHARMACEUTICALS INC SAYS "THERE IS NO MERIT TO CIVIL COMPLAINT FILED BY U.S. ATTORNEY FOR DISTRICT OF MASSACHUSETTS"
The U.S. Justice Department on Wednesday sued Regeneron Pharmaceuticals Inc, accusing it of using a charity that helps cover Medicare patients' drug costs as a means to pay kickbacks for using its expensive macular degeneration drug Eylea.
The U.S. Justice Department on Wednesday sued Regeneron Pharmaceuticals Inc, accusing it of using a charity that helps cover Medicare patients' drug costs as a means to pay kickbacks for using its expensive macular degeneration drug Eylea.
* KYMAB WINS SUPREME COURT CASE AGAINST REGENERON Source text for Eikon: Further company coverage:
* DUPIXENT® (DUPILUMAB) APPROVED IN CHINA FOR ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
Regeneron Pharmaceuticals Inc on Thursday said it has begun human testing of its experimental antibody cocktail as a treatment for COVID-19, the disease caused by the novel coronavirus.
Regeneron Pharmaceuticals Inc on Thursday said it has begun human testing of its experimental antibody cocktail as a treatment for COVID-19, the disease caused by the novel coronavirus.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.